T-3256336 | CAS#1266227-69-3 | IAP antagonist

MedKoo Cat#: 563179 | Name: T-3256336

Description:

WARNING: This product is for research use only, not for human or veterinary use.

T-3256336 is an orally available IAP antagonist. It act by selectively binding to and antagoning protein interactions involving cellular IAP-1 (cIAP-1), cIAP-2, and X-linked IAP (XIAP).

Chemical Structure

T-3256336

CAS#1266227-69-3

Theoretical Analysis

MedKoo Cat#: 563179

Name: T-3256336

CAS#: 1266227-69-3

Chemical Formula: C31H45F2N5O5

Exact Mass: 605.3389

Molecular Weight: 605.72

Elemental Analysis: C, 61.47; H, 7.49; F, 6.27; N, 11.56; O, 13.21

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

T-3256336; T 3256336; T3256336;

IUPAC/Chemical Name

(3S,7R,8aR)-2-{(2S)-2-(4,4-Difluorocyclohexyl)-2-[(N-methyl-L-alanyl)amino]acetyl}-N-[(4R)-3,4-dihydro-2H-chromen-4-yl]-7-ethoxyoctahydropyrrolo[1,2-a]pyrazine-3-carboxamide

InChi Key

WQLHYSFOEZZZDD-QAPMSZJWSA-N

InChi Code

InChI=1S/C31H45F2N5O5/c1-4-42-22-15-21-16-38(30(41)27(36-28(39)19(2)34-3)20-9-12-31(32,33)13-10-20)25(18-37(21)17-22)29(40)35-24-11-14-43-26-8-6-5-7-23(24)26/h5-8,19-22,24-25,27,34H,4,9-18H2,1-3H3,(H,35,40)(H,36,39)/t19-,21+,22+,24+,25-,27-/m0/s1

SMILES Code

O=C([C@H]1N(C([C@H](C2CCC(F)(F)CC2)NC([C@H](C)NC)=O)=O)C[C@](C[C@@H](OCC)C3)([H])N3C1)N[C@@H]4CCOC5=C4C=CC=C5

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 605.72 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Sumi H, Inazuka M, Morimoto M, Hibino R, Hashimoto K, Ishikawa T, Kuida K, Smith PG, Yoshida S, Yabuki M. An inhibitor of apoptosis protein antagonist T-3256336 potentiates the antitumor efficacy of the Nedd8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924). Biochem Biophys Res Commun. 2016 Nov 18;480(3):380-386. doi: 10.1016/j.bbrc.2016.10.058. Epub 2016 Oct 19. PubMed PMID: 27771247. 2: Sumi H, Inazuka M, Hashimoto K, Ishikawa T, Yoshida S, Yabuki M. T-3256336, a novel and orally available small molecule IAP antagonist, induced tumor cell death via induction of systemic TNF alpha production. Biochem Biophys Res Commun. 2016 Oct 14;479(2):179-185. doi: 10.1016/j.bbrc.2016.09.019. Epub 2016 Sep 5. PubMed PMID: 27608596. 3: Takeuchi S, Kojima T, Hashimoto K, Saito B, Sumi H, Ishikawa T, Ikeda Y. Screening and Characterization of Hydrate Forms of T-3256336, a Novel Inhibitor of Apoptosis (IAP) Protein Antagonist. Chem Pharm Bull (Tokyo). 2015;63(11):858-65. doi: 10.1248/cpb.c15-00262. PubMed PMID: 26521850. 4: Shiokawa Z, Hashimoto K, Saito B, Oguro Y, Sumi H, Yabuki M, Yoshimatsu M, Kosugi Y, Debori Y, Morishita N, Dougan DR, Snell GP, Yoshida S, Ishikawa T. Design, synthesis, and biological activities of novel hexahydropyrazino[1,2-a]indole derivatives as potent inhibitors of apoptosis (IAP) proteins antagonists with improved membrane permeability across MDR1 expressing cells. Bioorg Med Chem. 2013 Dec 15;21(24):7938-54. doi: 10.1016/j.bmc.2013.09.067. Epub 2013 Oct 12. PubMed PMID: 24169315. 5: Hashimoto K, Saito B, Miyamoto N, Oguro Y, Tomita D, Shiokawa Z, Asano M, Kakei H, Taya N, Kawasaki M, Sumi H, Yabuki M, Iwai K, Yoshida S, Yoshimatsu M, Aoyama K, Kosugi Y, Kojima T, Morishita N, Dougan DR, Snell GP, Imamura S, Ishikawa T. Design and synthesis of potent inhibitor of apoptosis (IAP) proteins antagonists bearing an octahydropyrrolo[1,2-a]pyrazine scaffold as a novel proline mimetic. J Med Chem. 2013 Feb 14;56(3):1228-46. doi: 10.1021/jm301674z. Epub 2013 Jan 29. PubMed PMID: 23298277. 6: Sumi H, Yabuki M, Iwai K, Morimoto M, Hibino R, Inazuka M, Hashimoto K, Kosugi Y, Aoyama K, Yamamoto S, Yoshimatsu M, Yamasaki H, Tozawa R, Ishikawa T, Yoshida S. Antitumor activity and pharmacodynamic biomarkers of a novel and orally available small-molecule antagonist of inhibitor of apoptosis proteins. Mol Cancer Ther. 2013 Feb;12(2):230-40. doi: 10.1158/1535-7163.MCT-12-0699. Epub 2012 Dec 12. PubMed PMID: 23243058.